Glenmark becomes the First Company in India to launch Teneligliptin + Dapagliflozin Fixed-Dose Combination, for Adults with Type 2 Diabetes, having Comorbidities

 

Mumbai: "Glenmark Pharmaceuticals Limited" (Glenmark), an innovation-driven global pharmaceutical company, became the first to launch 'Teneligliptin (20mg) + Dapagliflozin (5mg/10mg)' fixed-dose combination (FDC) for the treatment of adult patients with type 2 diabetes, especially the ones with Comorbidities. Marketed under the brand name Zita D; it contains Teneligliptin (20mg) + Dapagliflozin (5mg/10mg) and must be taken once daily under prescription to improve glycemic control & prevent complications in adult patients with type 2 diabetes, especially the ones with Comorbidities.

On the launch, Alok Malik, EVP & Business Head - India Formulations, Glenmark Pharmaceuticals, said, “Diabetes is growing in India at an alarming rate, and eight out of every ten diabetic patients suffer from Comorbidities. 'Glenmark' being a leader in the diabetes segment in India is proud to bring Zita D, a well-researched and affordable fixed dose combination, which will significantly improve the glycemic control in adult patients suffering from uncontrolled Type 2 diabetes, especially the ones with Comorbidities.”

Teneligliptin is a widely used DPP4i (Dipeptidyl Peptidase 4) inhibitor whereas Dapagliflozin is the most prescribed SGLT-2i (Sodium-glucose co-transporter 2) inhibitor for diabetic patients in the country. While Zita D is a promising treatment option in managing uncontrolled Type 2 diabetes with co-morbidities, this FDC has also proven to be effective among adult diabetic patients without Comorbidities. Glenmark's Zita D has priced at around INR 14 per tablet for FDC of Teneligliptin 20mg + Dapagliflozin 5mg, and INR 15 per tablet for FDC of Teneligliptin 20mg + Dapagliflozin 10mg, per day.

Glenmark’s Leadership in the diabetes segment:
'Glenmark' has a strong legacy of bringing new and effective treatment options for diabetic patients. In 2015, Glenmark revolutionized diabetes treatment in India by being the first to launch the DPP4 inhibitor – Teneligliptin, followed by a fixed-dose combination of Teneligliptin + Metformin. In continuation of its legacy, 'Glenmark' launched Remogliflozin, a novel SGLT-2 inhibitor in 2019 after its first global approval in India and subsequently launched its combinations with metformin and Vildagliptin. Earlier in 2022, Glenmark launched Sitagliptin and its FDCs, followed by Lobeglitazone.

Diabetes in India:
According to IQVIA™ sales data for the 12 months ending Sept. 2022, the market for oral anti-diabetic drugs in India is estimated to be INR 11,796 cr. with an annual growth of 7% against the corresponding period last year (MAT sept. 2021). As per the International Diabetes Federation (IDF), the prevalence of diabetes in India is expected to increase to 125 million by 2045i[i] Out of these, 77% of patients have uncontrolled diabetes iii. Moreover, about eight out of ten patients with diabetes also have one or more comorbidity in India.